Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
TGRN-321 + envafolimab
- Development stage
- Preclinical
- Lead developer
- 3D Medicines
- Modality
- Nanobodies (VHH) → Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous, Subcutaneous
01
Overview
TGRN-321 + envafolimab is an investigational combination therapy being developed by Simcere Pharmaceutical (Jiangsu Xiansheng) in collaboration with Tagworks Pharmaceuticals. TGRN-321 is a first-in-class antibody-drug conjugate (ADC) targeting Tumor-Associated Glycoprotein 72 (TAG72), utilizing Tagworks' proprietary 'Click-to-Release' technology. This platform allows for the systemic administration of a prodrug that is selectively activated at the tumor site by a secondary 'trigger' molecule, potentially enhancing the therapeutic index by reducing off-target toxicity. Envafolimab (KN035) is a subcutaneous PD-L1-targeting single-domain antibody (nanobody) already approved in China for certain oncology indications. The combination aims to leverage the targeted cytotoxic effects of the TAG72 ADC with the immune-potentiating effects of PD-L1 checkpoint inhibition to treat various TAG72-expressing solid tumors.
- Brand names
- Enweida
- Other names
- TGRN-321 + ALN + PD-L1TGRN-321 + PD-L1TGRN-321 + Envafolimab
02
Targets
TAG-72CD274 (Programmed cell death protein 1 ligand 1)
Beyond the preview
Go deeper on TGRN-321 + envafolimab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on TGRN-321 + envafolimab.